Biotech | May 04, 2022
HPRA completes audit of Biocon Biologics New mAbs drug substance facility
The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency
